The Enterprise Value as of December 2024 (TTM) for Rigel Pharmaceuticals, Inc. (RIGL) is 310.63M

According to Rigel Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 310.63M. This represents a change of 24.02% compared to the average of 250.47M of the last 4 quarters.

Rigel Pharmaceuticals, Inc. (RIGL) Historical Enterprise Value (quarterly & annually)

How has RIGL Enterprise Value performed in the past?

The mean historical Enterprise Value of Rigel Pharmaceuticals, Inc. over the last ten years is 336.98M. The current 310.63M Enterprise Value has changed 9.12% with respect to the historical average. Over the past ten years (40 quarters), RIGL's Enterprise Value was at its highest in in the June 2021 quarter at 688.75M. The Enterprise Value was at its lowest in in the June 2024 quarter at 171.87M.

Rigel Pharmaceuticals, Inc. (RIGL) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Rigel Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Rigel Pharmaceuticals, Inc. (RIGL) Average Enterprise Value

How has RIGL Enterprise Value performed in the past?

The current Enterprise Value of Rigel Pharmaceuticals, Inc. (RIGL) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Rigel Pharmaceuticals, Inc. (RIGL) Enterprise Value vs. Peers

How is RIGL’s Enterprise Value compared to its peers?

Rigel Pharmaceuticals, Inc.’s Enterprise Value is greater than Fortress Biotech, Inc. (60.71M), greater than Reviva Pharmaceuticals Holdings, Inc. (70.91M), less than CTI BioPharma Corp. (1.22B), greater than Ocuphire Pharma, Inc. (-9671816.00), greater than Nabriva Therapeutics plc (-2646928.00), greater than Eiger BioPharmaceuticals, Inc. (28.35M), greater than Pieris Pharmaceuticals, Inc. (-1407736.00), greater than Cidara Therapeutics, Inc. (41.45M), greater than X4 Pharmaceuticals, Inc. (79.21M), less than Mereo BioPharma Group plc (445.16M), greater than Inozyme Pharma, Inc. (215.58M), greater than Terns Pharmaceuticals, Inc. (234.86M), greater than Leap Therapeutics, Inc. (48.29M), greater than Zura Bio Limited (-32822399.00), greater than Enveric Biosciences, Inc. (40.99K), greater than eFFECTOR Therapeutics, Inc. (4.74M), greater than Immix Biopharma, Inc. (41.37M), greater than Elevation Oncology, Inc. (16.72M), less than Day One Biopharmaceuticals, Inc. (859.59M), greater than Acumen Pharmaceuticals, Inc. (103.15M), less than VectivBio Holding AG (848.58M),

Build a custom stock screener for Rigel Pharmaceuticals, Inc. (RIGL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Rigel Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Rigel Pharmaceuticals, Inc. (RIGL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Rigel Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.